Paul Peter Tak, M.D., Ph.D., FMedSci
2021
In 2021, Paul Peter Tak, M.D., Ph.D., FMedSci earned a total compensation of $956.8K as President and Chief Executive Officer at Candel Therapeutics, a 64% decrease compared to previous year.
Compensation breakdown
| Bonus | $85,000 |
|---|---|
| Non-Equity Incentive Plan | $167,500 |
| Salary | $545,116 |
| Other | $159,184 |
| Total | $956,800 |
FMedSci received $545.1K in salary, accounting for 57% of the total pay in 2021.
FMedSci also received $85K in bonus, $167.5K in non-equity incentive plan and $159.2K in other compensation.
Rankings
In 2021, Paul Peter Tak, M.D., Ph.D., FMedSci's compensation ranked 8,925th out of 12,406 executives tracked by ExecPay. In other words, FMedSci earned more than 28.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,925 out of 12,406 | 28th |
Division Manufacturing | 3,953 out of 5,492 | 28th |
Major group Chemicals And Allied Products | 1,735 out of 2,368 | 27th |
Industry group Drugs | 1,544 out of 2,089 | 26th |
Industry Biological Products, Except Diagnostic Substances | 337 out of 452 | 25th |
Source: SEC filing on September 2, 2022.
FMedSci's colleagues
We found three more compensation records of executives who worked with Paul Peter Tak, M.D., Ph.D., FMedSci at Candel Therapeutics in 2021.